Market Tracker

12/12 3:01am ET

Incyte Corp (NASDAQ:INCY)

97.25
Delayed Data
As of Dec 11
 +0.67 / +0.69%
Today’s Change
92.91
Today|||52-Week Range
153.15
-3.01%
Year-to-Date
Incyte (INCY) Reports Phase III Follow-Up Data for Jakafi
Dec 11 / Zacks.com - Paid Partner Content
4 Drug/Biotech Stocks That Could Be Buyout Targets in 2018
Dec 11 / Zacks.com - Paid Partner Content
3 Stocks in Focus as Biotech M&A Hopes for 2018 Rise
Dec 11 / Zacks.com - Paid Partner Content
5 Top-Ranked Drug Stocks that are Broker Favorites
Dec 05 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close96.58
Today’s open96.25
Day’s range96.11 - 97.58
Volume1,363,813
Average volume (3 months)1,634,600
Market cap$20.4B
Data as of 4:00pm ET, 12/11/2017

Growth & Valuation

Earnings growth (last year)+1,700.00%
Earnings growth (this year)-330.50%
Earnings growth (next 5 years)+75.95%
Revenue growth (last year)+46.70%
P/E ratioNM
Price/Sales17.60
Price/Book43.48

Competitors

 Today’s
change
Today’s
% change
ZTSZoetis Inc-0.11-0.15%
ALXNAlexion Pharmaceutic...-2.56-2.24%
BAXBaxter International...+0.09+0.14%
MYLMylan NV+0.82+2.12%
Data as of 4:02pm ET, 12/11/2017

Financials

Next reporting dateFebruary 14, 2018
EPS forecast (this quarter)-$0.53
Annual revenue (last year)$1.1B
Annual profit (last year)$104.2M
Net profit margin9.43%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, President &
Chief Executive Officer
Hervé Hoppenot
Chief Financial Officer &
Executive Vice President
David W. Gryska
Corporate headquarters
Wilmington, Delaware

Forecasts